海外の治験の状況「前立腺癌」での検索結果
266件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
- Prostate Cancer;Prostate Cancer;Prostate Cancer;Prostate Cancer
- Belgium, Canada, Italy, Malta, Netherlands, Slovakia, South Africa, Switzerland, Turkey, United Kingdom, United States
- 1999-11-01
Not recruiting
- The effect of intermittent versus continuous androgen deprivation therapy in Chinese patients with advanced prostate cancer: A prospective controlled Trial from China
- prostate cancer
- Australia, China, Outside
- 2013-01-29
Not recruiting
- Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
- Prostate Cancer
- Australia, Czech Republic, Czechia, France, Greece, Italy, Netherlands, Romania, Spain, United Kingdom, United States
- 2011-12-02
Not recruiting
- Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
- Prostate Cancer
- Argentina, Australia, Chile, Colombia, France, Germany, Italy, Mexico, Netherlands, Spain, United Kingdom, United States
- 2014-10-29
Not Recruiting
- Safety and Efficacy study of ipilimumab 3 mg/kg versus ipilimumab 10 mg/kg in subjects with metastatic castration resistant prostate cancer who are chemotherapy naive
- Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer br>MedDRA version: 17.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Chile, Colombia, France, Germany, Italy, Mexico, Netherlands, Spain, United Kingdom
- 2014-09-22
Not recruiting
- The effects of a herbal medicine combination in men with biochemically recurrent prostate cancer
- Prostate cancer
- Australia
- 2014-08-25
Not Recruiting
- A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy
- Cancer Cataract Low Bone Mineral Density Osteopenia Osteoporosis Prostate Cancer
- Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States of America
- 2012-08-23
Not Recruiting
- A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
- Metastatic Castrate Resistant Prostate Cancer
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Estonia, France, Germany, Greece, India, Ireland, Italy, Latvia, Lebanon, Lithuania, Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Poland, Republic of Korea, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States of America
- 2012-07-16
Not Recruiting
- A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, South Africa, Spain, Sweden, Switzerland, Taiwan, Province of China, Turkey, United Kingdom, United States
- 2012-04-30
Not Recruiting
- REGISTRY OF TREATMENT PATTERNS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) WITH PROGRESSION DURING OR AFTER DOCETAXEL-BASED REGIMEN
- metastatic castration registant prostate cancer
- Africa, Asia(except Japan), Europe, Japan, South America
- 2012-04-12